Markets 

Pfizer begins testing use of pneumococcal vaccine along with COVID-19 booster shot

FILE PHOTO: A person walks past a Pfizer logo amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegri/File Photo

(Corrects spelling of pneumococcal in headline)

(Reuters) – Pfizer Inc said on Monday it has started immunizing the first patients in a new study looking at administering the company’s 20-valent pneumococcal conjugate vaccine candidate following a booster dose of the Pfizer-BioNTech COVID-19 shot.

The study will include 600 adults over 65 years who will be recruited from the late-stage study of the Pfizer-BioNTech COVID-19 vaccine, and will have received their second dose of the vaccine at least six months prior to entering the co-administration study, the company said.

(This story has been refiled to correct spelling of pneumococcal in headline)

Source: Read Full Article

You May Also Like

Facebook wraps up deals with Australian media firms, TV broadcaster SBS excluded

Myanmar's neighbours press for Suu Kyi's release, restoration of democracy

London Fund Managers See Post-EU Threat to $2 Trillion Business